ArticleJournal of cellular and molecular medicine2022
LRP5 promotes cancer stem cell traits and chemoresistance in colorectal cancer.
Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Chronically Established ρJournal of Cancer · 2026Article
- Immunoexpression of stem cell markers CD44, CD133, ALDH1-2, and LGR5 in colorectal carcinoma and their association with clinicopathological tumor characteristics.Einstein (Sao Paulo, Brazil) · 2026Article
- Gut dysbiosis conveys psychological stress to activate LRP5/β-catenin pathway promoting cancer stemness.Signal transduction and targeted therapy · 2025Article
- Colorectal cancer stem cells crosstalk in tumor immune microenvironment and targeted therapeutic strategies.Frontiers in immunology · 2025Review
- Bacteriocins from Lactic Acid Bacteria Could Modulate the Wnt Pathway: A Possible Therapeutic Candidate for the Management of Colorectal Cancer- AnAnti-cancer agents in medicinal chemistry · 2025Article
- LRP5 enhances glioma cell proliferation by modulating the MAPK/p53/cdc2 pathway.International journal of medical sciences · 2025Article
- Hsa_circ_0023179 modulated the processes of proliferation, apoptosis, and EMT in non-small cell lung cancer cells via the miR-615-5p/CDH3 axis.Biomolecules & biomedicine · 2024Article
- Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis.Clinical & experimental metastasis · 2024Review
- Integration of single-cell sequencing and bulk RNA-seq to identify and develop a prognostic signature related to colorectal cancer stem cells.Scientific reports · 2024Article
- Knockdown of LRP5 Promotes Proliferation and Invasion of Tongue Squamous Cell Carcinoma through Compensatory Activation of Akt Signaling.Journal of Cancer · 2024Article
- Differences and Similarities between Colorectal Cancer Cells and Colorectal Cancer Stem Cells: Molecular Insights and Implications.ACS omega · 2023Article
- Article
- Review
- Recent advances in targeted drug delivery systems for resistant colorectal cancer.Cancer cell international · 2022Review
- LRP5 promotes cancer stem cell traits and chemoresistance in colorectal cancer.Journal of cellular and molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overactivation of canonical Wnt/β-catenin pathway and the maintenance of cancer stem cells (CSCs) are essential for the onset and malignant progression of most human cancers. However, their regulatory mechanism in colorectal cancer (CRC) has not yet been well demonstrated. Low-density lipoprotein receptor-related protein 5 (LRP5) has been identified as an indispensable co-receptor with frizzled family members for the canonical Wnt/β-catenin signal transduction. Herein, we show that activation of LRP5 gene promotes CSCs-like phenotypes, including tumorigenicity and drug resistance in CRC cells, through activating the canonical Wnt/β-catenin and IL-6/STAT3 signalling pathways. Clinically, the expression of LRP5 is upregulated in human CRC tissues and closely associated with clinical stages of patients with CRC. Further analysis showed silencing of endogenous LRP5 gene is sufficient to suppress the CSCs-like phenotypes of CRC through inhibiting these two pathways. In conclusion, our findings not only reveal a regulatory cross-talk between canonical Wnt/β-catenin signalling pathway, IL-6/STAT3 signalling pathway and CD133-related stemness that promote the malignant behaviour of CRC, but also provide a valuable target for the diagnosis and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.